Research Article| Volume 6, ISSUE 4, P198-199, April 1997

Download started.


Neuroprotection: before and after thrombolysis

  • Patrick D. Lyden
    Address reprint requests to Patrick D. Lyden, MD, Department of Neuroscience, UCSD Stroke Center, OPC 3rd Floor, Suite 3, 200 W Arbor Dr, San Diego, CA 92103-8466.
    UCSD Stroke Center, University of California, San Diego, CA., USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
        Tissue plasminogen activator for acute ischemic stroke.
        N Engl J Med. 1995; 333: 1581-1587
        • Feldmann E
        • Gordon N
        • Brooks JM
        • Brass LM
        • Fayad PB
        • Sawaya KL
        • et al.
        Factors associated with early presentation of acute stroke.
        Stroke. 1993; 24: 1805-1810
        • Harper GD
        • Haigh RA
        • Potter JF
        • Castleden CM
        Factors delaying hospital admission after stroke in Leicestershire.
        Stroke. 1992; 23: 835-838
        • Alberts MJ
        • Perry A
        • Dawson DV
        • Bertels C
        Effects of public and professional education on reducing the delay in presentation and referral of stroke patients.
        Stroke. 1992; 23: 352-356
        • Grotta J
        The current status of neuronal protective therapy: why have all neuronal protective drugs worked in animals but none so far in stroke patients?.
        Cerebrovasc Dis. 1994; 4: 115-120
        • Lyden PD
        • Zivin JA
        Hemorrhagic transformation after cerebral ischemia: Mechanisms and incidence.
        Cerebrovasc Brain Met Rev. 1993; 5: 1-16
        • Hsu CY
        Criteria for valid preclinical trials using animal stroke models.
        Stroke. 1993; 24: 633-636
        • Pellegrini-Giampietro DE
        • Cozzi A
        • Moroni F
        The glycine antagonist and free radical scavenger 7-C1-thiokynurenate reduces CA1 ischemic damage in the gerbil.
        Neuroscience. 1994; 63: 701-709
        • Newell DW
        • Barth A
        • Malouf AT
        Glycine site NMDA receptor antagonists provide protection against ischemia-induced neuronal damage in hippocampal slice cultures.
        Brain Res. 1995; 675: 38-44
        • Lyden PD
        GABA and Neuroprotection.
        in: Green AR Cross AJ Neuroprotective agents and cerebral ischaemia. Academic, London1997: 233-258
        • Hallenbeck JM
        • Frerichs KU
        Stroke therapy. It may be time for an integrated approach.
        Arch Neurol. 1993; 50: 768-770